IFNB1 and relapsing-remitting multiple sclerosis: We conducted the present non-randomized clinical trial to assess the effectiveness of fingolimod on reduction of disability and relapse rate in Iranian patients with relapsing-remitting MS (RRMS) in comparison with IFNβ.